Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(6 sites)
United States
Precision NextGen Oncology, Beverly Hills, California OPN Healthcare, Inc, Glendale, California University of Southern California, Los Angeles, California Vanderbilt University Medical Center, Nashville, Tennessee Baylor, Scott and White Research Institute, Dallas, Texas Northwest Medical Specialties, Tacoma, Washington